Prof Ghosh presented data from the UNITI studies exploring ustekinumab in primary or secondary nonresponders to TNF agonists (UNITI-1) and conventional therapy failures (UNITI-2).
![EMJ Gastroenterology 11 [Supplement 3] 2022 Feature Image](https://emj.emg-health.com/wp-content/uploads/sites/2/2022/07/EMJ-Gastroenterology-11-Supplement-3-2022-Feature-Image-940x563.png)
13 Mins
1st
July
2022
Allergy & Immunology
Login to continue
Members
Create Account
Create your own personal healthcare feed, full of the latest content from across our divisions.
Register
